Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%

By Yahoo! Finance | Jul 30, 2024 at 08:39 AM EST

Retail investors own 57% of Galectin Therapeutics stock, followed by insiders at 20%, and institutions at a significant stake. Hedge funds control 9.5% of shares. Analyst sentiments and insider ownership suggest potential growth for the company.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.